Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61700 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2POLB | |
| SCHEMBL27477402 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2POLB | |
| SCHEMBL27495140 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2POLB | |
| SCHEMBL28007708 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2POLB | |
| SCHEMBL27573 | 0.78 | ALDH1A1 (0.31) | — | |
| SCHEMBL2875795 | 0.77 | CNR1 (0.33) | — | |
| SCHEMBL2879163 | 0.76 | KIF11 (0.38) | GABRA1GABRB2POLB | |
| SCHEMBL1561562 | 0.75 | TSHR (0.42) | GABRA1GABRB2POLB | |
| Magnesium Chloride Anhydrous SCHEMBL27957567 | 0.73 | GABRA1 (0.39) | GABRA1GABRB2POLB | |
| SCHEMBL27957557 | 0.73 | GABRA1 (0.44) | GABRA1GABRB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2018-07-24 | — | — | US | claimed |
| EP-3134391-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2017-03-01 | — | — | EP | claimed |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2017-02-16 | — | — | US | claimed |
| WO-2015162166-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2015-10-29 | — | — | WO | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | claimed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | GABRA1 4419/4885GABRB2 3789/4885POLB 791/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | GABRA1 3675/4885GABRB2 3204/4885POLB 2000/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | GABRA1 4419/4885GABRB2 3789/4885POLB 791/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | GABRA1 4222/4885GABRB2 3994/4885POLB 2121/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | GABRA1 4419/4885GABRB2 3789/4885POLB 791/4885 |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | GABRA1 2384/4885GABRB2 2055/4885POLB 2249/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | GABRA1 3675/4885GABRB2 3204/4885POLB 2000/4885 |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | GABRA1 4329/4885GABRB2 3636/4885POLB 705/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | GABRA1 3675/4885GABRB2 3204/4885POLB 2000/4885 |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | GABRA1 2391/4885GABRB2 2080/4885POLB 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.